<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Antiphospholipid-protein syndrome (APS) comprises venous and <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo>, <z:hpo ids='HP_0005268'>spontaneous abortion</z:hpo> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> in patients with antiphospholipid-protein antibodies (<z:chebi fb="21" ids="53713">APA</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>Such antibodies are detected by immunoenzymatic (ELISA) methods (e.g. anticardiolipin antibodies-ACL) or coagulation assays (<z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>-LA) </plain></SENT>
<SENT sid="2" pm="."><plain>APS in patients showing other symptoms of <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> is called secondary antiphospholipid-protein syndrome </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of the study was to find relation between history of <z:mp ids='MP_0005048'>thrombosis</z:mp> and <z:chebi fb="21" ids="53713">APA</z:chebi> in a group of patients with <z:e sem="disease" ids="C0409974" disease_type="Disease or Syndrome" abbrv="">lupus erythematosus</z:e> and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e>-like disease </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> was detected by a three step procedure using <z:chebi fb="0" ids="16247">phospholipid</z:chebi> dependent clotting assays and anticardiolipin antibodies were measured by ELISA </plain></SENT>
<SENT sid="5" pm="."><plain>We studied 95 subjects (91 women, 4 men) suffering from <z:e sem="disease" ids="C0409974" disease_type="Disease or Syndrome" abbrv="">lupus erythematosus</z:e> (67 patients) and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e>-like-disease (28 patients) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> was found in 26, anticardiolipin antibodies IgG in 34 and IgM in 27 subjects </plain></SENT>
<SENT sid="7" pm="."><plain>In a retrospective study 40 thrombotic events were detected in 36 patients; <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo> in 19, <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> in 7, ischaemic <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> events in 13 and <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> in one </plain></SENT>
<SENT sid="8" pm="."><plain><z:mp ids='MP_0005048'>Thrombosis</z:mp> was present more often in subjects with LA (61%) and ACL IgG (52%) than in subjects without these antibodies (24%) (p = 0.004 and 0.015, respectively) </plain></SENT>
<SENT sid="9" pm="."><plain>ACL IgM antibodies were not related to thrombotic episodes </plain></SENT>
<SENT sid="10" pm="."><plain>The ACL IgG antibodies and LA are helpful in identifying subjects at risk factors of venous and <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> among patients suffering from <z:e sem="disease" ids="C0409974" disease_type="Disease or Syndrome" abbrv="">lupus erythematosus</z:e> and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e>-like disease </plain></SENT>
</text></document>